On January 4th, the National Health Commission, Ministry of Industry and Information Technology, and other departments announced that the fourth batch of encouraged generic drug catalogs includes 21 varieties and 47 specifications, covering drugs used in fields such as anti-tumor, neurological, assisted reproductive, and radiological diagnosis. It is reported that the fourth batch of catalogs will continue to be guided by the treatment needs of patients. Priority will be given to the inclusion of new targets and products with new mechanisms of action in response to weak R&D links in Chinese enterprises. Diillegal forest can alleviate moderate to severe itching related to chronic kidney disease in hemodialysis patients; Four domestically unlisted radioactive drugs, covering treatment, diagnosis, and localization drugs. Generic drugs play a crucial role in maintaining patient health. In the popular movie "I'm Not a Medicine God" a few years ago, many patients could only hope for relatively affordable generic drugs due to the high prices of genuine drugs that they couldn't afford. However, the process of obtaining these generic drugs is fraught with difficulties and even involves legal risks. This reflects the urgent need of patients for generic drugs and the helpless situation of facing a shortage of drugs. In real life, similar situations are not uncommon. Although the current situation has significantly improved, there are still many patients who are trapped in the dilemma of having no drugs available due to a lack of generic drugs and unaffordable prices of original drugs. The newly listed drugs in this catalog are not only urgently needed by patients, but also very down-to-earth and carefully considered. For example, regarding the promotion of fertility policies, priority has been given to using assisted reproductive drugs with low adverse reactions, which is undoubtedly a blessing for families who aspire to have their own children. For example, while considering the accessibility of medication, priority should be given to selecting products with existing clinical practices in China, such as Diclofenac for the treatment of rare disease Duchenne muscular dystrophy. The inclusion of such drugs makes it easier to alleviate the urgent needs of relevant patients. Equally commendable is that the fourth batch of catalogs prioritizes the inclusion of products recommended by overseas first-line guidelines, while considering their effectiveness. Taking Suvorosen, which is used to treat insomnia, as an example, it mainly solves the problems of difficulty falling asleep and not sleeping long, and can also reduce the adverse reactions of daytime sleepiness and fatigue. The insomnia treatment drugs already on the market in our country may have certain limitations, and the inclusion of Suvorosen can make up for these shortcomings and provide more choices for clinical practice. This means that patients have a better treatment plan for insomnia, and can choose medication that is more suitable for their specific situation, thereby improving treatment effectiveness and sleep quality. Of course, to improve patients' access to generic drugs, the key is to implement effective incentive policies. The National Health Commission, in conjunction with relevant departments, has established a communication and consultation mechanism to promote the coordination of supporting policies such as encouraging the research and development, registration, production, use, and reimbursement of generic drugs in accordance with their responsibilities, promoting rational use, and ensuring drug supply. This measure is crucial. Only by closely coordinating various links and forming a complete policy chain can we ensure smooth and unobstructed promotion of generic drugs from research and development to patients' hands. The fourth batch of encouraged generic drug catalogs fully considers the actual needs of patients in the selection of varieties. Whether it is for common or rare diseases, whether it is for therapeutic or adjuvant drugs, we strive to provide patients with higher quality and more effective choices. This approach that closely adheres to the needs of people's livelihood not only reflects humanistic care for patients, but also points out the direction for the development of generic drugs in China. Only by continuously meeting the needs of patients can the generic drug industry gain sustainable development momentum and continue to contribute to solving the problem of patients seeking medical treatment and medication. (New Society)